Nicholson, C. David
Known title: DirectorCIK: 0001636168
Associated companies
Transaction History
| ATNM | ▲ Buy | Grant | 62,800 | $0 | 9/2/2026 | View on chart |
| ATNM | ▲ Buy | Grant | 62,800 | $0 | 9/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Actinium Announces ATNM-400 Presentation and CFO Appointment
Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.
Actinium Announces ATNM-400 Presentation and CFO Appointment. Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.